Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BioPharma Dive
biopharmadive.com > news > moonwalk-series-b-obesity-rna-interference > 829784

Moonwalk reloads with $70M and new RNAi prospects for obesity

6+ day, 11+ hour ago   (331+ words) The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027. When Moonwalk Biosciences launched in 2024, it set ambitious plans to mine the epigenome for…...

Longevity.Technology
longevity.technology > news > moonwalk-raises-70m-for-adipose-targeted-rnai

Moonwalk raises $70m for adipose-targeted RNAi

4+ day, 23+ hour ago   (466+ words) Moonwalk CEO and cofounder Alex Aravanis told Longevity.Technology that the company believes its preclinical body-composition findings arise from acting directly on adipose rather than indirectly through appetite. “Our approach is fundamentally different because MW101 is designed to act directly on…...

@PRNewswire
prnewswire.com > news-releases > harmoni-raises-10-million-series-a-led-by-bessemer-venture-partners-and-unveils-hal-ai-built-for-the-front-lines-of-manufacturing-302873736.html

Harmoni Raises $10 Million Series A Led by Bessemer Venture Partners and Unveils HAL, AI Built for the Front Lines of Manufacturing

5+ day, 4+ hour ago   (246+ words) Sep 09, 2026, 08:00 ET Funding will accelerate product innovation, go-to-market expansion, and the continued advancement of HAL, context-aware manufacturing AI delivered directly to the point of production. AKRON, Ohio and NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Harmoni, the Factory Orchestration platform for manufacturers, today…...

Yahoo Finance
finance.yahoo.com > healthcare > articles > 4bio-capital-leads-oversubscribed-33-110500557.html

4BIO Capital leads oversubscribed $33 Million Seed Financing of Cloverleaf Bio, Advancing Novel RNA-Based Cancer Therapeutics

6+ day, 5+ hour ago   (142+ words) 4BIO Capital led upsized and oversubscribed round which includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platform Financing will support proof of concept in hepatocellular carcinoma and…...

BioSpace
biospace.com > press-releases > moonwalk-biosciences-announces-70-million-series-b-financing-to-advance-adipose-targeted-rnai-therapies-for-obesity-and-cardiometabolic-diseases

Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases

5+ day, 20+ hour ago   (468+ words) BioSpace Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture…...

BioXconomy
bioxconomy.com > investment > moonwalk-biosciences-glides-into-clinic-with-70m-series-b-funding

Moonwalk Biosciences glides into clinic with $70m Series B

6+ day, 3+ hour ago   (402+ words) Moonwalk Biosciences has closed a $70 million Series B to push adipose-targeted RNAi obesity candidate into the clinic. Moonwalk is developing small interfering RNA (siRNA) therapeutics designed to act directly on adipose tissue, targeting non-incretin biology inside the fat cell itself....

@genbio
genengnews.com > topics > drug-discovery > moonwalk-to-use-70-million-to-develop-rnai-therapies-for-obesity-cardiometabolic-disease

Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

5+ day, 23+ hour ago   (475+ words) Genetic Engineering and Biotechnology News Biotech company Moonwalk Biosciences announced that it has raised $70 million from an oversubscribed series B financing round. The company plans to use the funds to continue developing its adipose-targeted RNAi therapies for obesity and cardiometabolic…...

Endpoints News
endpoints.news > arpa-h-awards-125m-for-manufacturing-custom-rna-therapies-on-demand

ARPA-H awards $125M for manufacturing custom RNA therapies on demand

1+ week, 5+ day ago   (84+ words) Endpoints News ARPA-H awards $125M for man­u­fac­tur­ing cus­tom RNA ther­a­pies on de­mand The dream of mak­ing per­son­al­ized ge­net­ic med­i­cines at a mo­ment’s no­tice…...

Pulse 2.0
pulse2.com > runable-raises-21-million-series-a-as-ai-agent-hits-2-million-arr-in-3-weeks-and-1-5-million-users

Runable Raises $21 Million Series A As AI Agent Hits $2 Million ARR In 3 Weeks And 1.5 Million Users

2+ week, 4+ day ago   (664+ words) Runable has raised $21 million in Series A funding as its AI agent platform expands rapidly among small businesses looking to automate not only software creation, but also customer acquisition, marketing and day-to-day operations. Susquehanna Venture Capital and Nexus Venture Partners…...

Ascendants
ascendants.in > business-stories > runable-raises-21m-series-a-susquehanna-nexus-2m-arr

Runable Raises $21M Series A After Hitting $2M ARR in Three Months

2+ week, 4+ day ago   (519+ words) Agentic AI startup Runable has raised $21 million in a Series A round co-led by Susquehanna and Nexus Venture Partners, with existing investor Together Fund also participating. The company plans to put the new capital behind product expansion, growth tools and…...